Author

Diane Heiser

Prelude Therapeutics Incorporated (United States)ORCID 0009-0008-1757-914XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Aishwarya KulkarniiD· 1 shared Alberto J. ArribasiD· 1 shared Amit VermaiD· 1 shared Anastasios StathisiD· 1 shared Andrea RinaldiiD· 1 shared Ariel A. Fromowitz· 1 shared Daniel T. StarczynowskiiD· 1 shared David ShechteriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aishwarya KulkarniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 11, 2026

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors

Eleonora Cannas, Alberto J. Arribas, Luciano Cascione…·Francesco Bertoni

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologyScience Translational MedicinePeer-reviewedMay 7, 2025

Broad de-regulated U2AF1 splicing is prognostic and augments leukemic transformation via protein arginine methyltransferase activation

Meenakshi Venkatasubramanian, Leya Y Schwartz, Nandini Ramachandra…·Nathan Salomonis

The paper identifies a splicing mechanism in AML independent of mutations, showing it drives poor prognosis and can be targeted with PRMT5 inhibition.

12 citations

humanbulk RNA-seq

𝕏 PostBluesky